Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, Trump named RFK Jr. to lead the HHS, placing an overhang on XBI and vaccine makers PFE, GSK, MRNA, MRK, and SNY. BNTX and MRK made moves in the PD- 1/VEGF space.</li><li>ABBV’s costly neuro play failed, removing the main threat to BMY’s Cobenfy. AMGN was rattled by bone loss data for its obesity drug. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, Trump named RFK Jr. to lead the HHS, placing an overhang on XBI and vaccine makers PFE, GSK, MRNA, MRK, and SNY. BNTX and MRK made moves in the PD- 1/VEGF space.ABBV’s costly neuro play failed, removing the main threat to BMY’s Cobenfy. AMGN was rattled by bone loss data for its obesity drug. 

Biopharma Week in Review - November 18, 2024

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, SGMO got an even faster FDA path for Fabry gene therapy, VKTX built more anticipation for upcoming oral <span style="font-size: var(--content-font-size);">GLP-1 data, and ITRM crossed the antibiotic finish line at last. </span></li><li>AMGN showed at-risk confidence with a favorable court ruling versus REGN, VRTX pain data was as expected, NVO’s oral GLP- 1 in diabetes also benefited CVD, and ZLAB was lifted by niche lung cancer data. </li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, SGMO got an even faster FDA path for Fabry gene therapy, VKTX built more anticipation for upcoming oral GLP-1 data, and ITRM crossed the antibiotic finish line at last. AMGN showed at-risk confidence with a favorable court ruling versus REGN, VRTX pain data was as expected, NVO’s oral GLP- 1 in diabetes also benefited CVD, and ZLAB was lifted by niche lung cancer data. 

Biopharma Week in Review - October 28, 2024

<ul>
<li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li>
<li>Last week, BMY received landmark antipsychotic approval, while BHVN finally scored a win in rare genetic SCA.</li>
<li>AMGN had approvable data in atopic dermatitis and gMG, but not enough to dethrone REGN and ARGX. </li>
</ul>


We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.
Last week, BMY received landmark antipsychotic approval, while BHVN finally scored a win in rare genetic SCA.
AMGN had approvable data in atopic dermatitis and gMG, but not enough to dethrone REGN and ARGX. 


Biopharma Week in Review - September 30, 2024

Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Cross Asset Strategy

<ul><li>Technically, the SET Index is expected to fall, with the support at 1,265/1,250 points and the resistance at 1,281/1,286 points.</li><li>In the short term, the chart pattern shifted from an uptrend to a downtrend after the index reached a new low for the year at 1,274.25 points, compared to the previous low of 1,281.87 points on June 29, 2024.</li><li>We maintain our recommendation that investors take profit and wait to buy back when there is a new uptrend signal.</li></ul>

Technically, the SET Index is expected to fall, with the support at 1,265/1,250 points and the resistance at 1,281/1,286 points.In the short term, the chart pattern shifted from an uptrend to a downtrend after the index reached a new low for the year at 1,274.25 points, compared to the previous low of 1,281.87 points on June 29, 2024.We maintain our recommendation that investors take profit and wait to buy back when there is a new uptrend signal.

<ul><li>Technically, we expect the SET Index to move sideways up, with the resistance at 1,376/1,384 points (50-day EMA and 75-day EMA) and the support at 1,365/1,355 points.</li><li>Overall, the index is moving in a downtrend pattern within the range of 1,320-1,410 points.</li><li>However, in the short term, there was an uptrend signal for the first time after a positive breakout signal occurred on Tuesday, due to the index managing to breach the resistance of 1,365 points for the first time in five trading days.</li></ul>

Technically, we expect the SET Index to move sideways up, with the resistance at 1,376/1,384 points (50-day EMA and 75-day EMA) and the support at 1,365/1,355 points.Overall, the index is moving in a downtrend pattern within the range of 1,320-1,410 points.However, in the short term, there was an uptrend signal for the first time after a positive breakout signal occurred on Tuesday, due to the index managing to breach the resistance of 1,365 points for the first time in five trading days.

EU's Manufacturing PMI in April and Earnings Results

United States

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Amgen (AMGN UW)

Biopharma Week in Review - November 18, 2024

ABBV’s costly neuro play failed, removing the main threat to BMY’s Cobenfy. AMGN was rattled by bone loss data for its obesity drug.

Water Tower Research

Biopharma Week in Review - October 28, 2024

Last week, SGMO got an even faster FDA path for Fabry gene therapy, VKTX built more anticipation for upcoming oral GLP-1 data, and ITRM crossed the...

Water Tower Research

Biopharma Week in Review - September 30, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BMY received...

Water Tower Research

US Trade Balance and EU Retail Sales

Technically, the SET Index is expected to fall, with the support at 1,265/1,250 points and the resistance at 1,281/1,286 points. In the short...

Krungthai XSpring

EU's Manufacturing PMI in April and Earnings Results

Technically, we expect the SET Index to move sideways up, with the resistance at 1,376/1,384 points (50-day EMA and 75-day EMA) and the support at...

Krungthai XSpring

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)